leader in PROSTATE CANCER research

The Center for Prostate Disease Research (CPDR), is an interdisciplinary translational prostate cancer research program of the USU Department of Surgery and the John P. Murtha Cancer Center at the Walter Reed National Military Medical Center. The CPDR enriches the training of the next generation of physicians and scientists who directly benefit the quality, outcomes, and stability of the military health care delivery system.

CPDR conducts state-of-the-art clinical, basic science, and epidemiologic research, with an emphasis on precision medicine to enhance the readiness of active duty personnel in conjunction with the continuum of medical care for military retirees and beneficiaries

The CPDR integrates expertise of urologic and medical oncologists, cancer biologists, genitourinary pathologists, epidemiologists, bio-statisticians, medical technologists, research nurses, patient educators, bioinformaticians, and program management specialists. All these areas of expertise provide state-of-the-art resources for in-house and collaborative research in prostate cancer. Ground-breaking discoveries through strong academic and clinical research (over 25 years and over 480 publications) have led to major advances in translational prostate cancer research and treatment reflecting the synergy of expertise and resources of CPDR’s four pillars:



scientific articles have been published in the past 25 years


units from 7000+ patients


military patients with prostate cancer integrating 5 DoD and 1 civilian medical centers in Multi-Center National Database


years of discoveries

Groundbreaking Discoveries

Groundbreaking Discoveries focusing on identification and the function of prostate cancer causal genes, e.g., ERG (PMID: 15750627,  PMID: 18542058PMID: 28439080PMID: 29712692); novel insights into health disparity-related genomic differences in prostate cancer, e.g. ERG, PTEN and LSAMP (PMID: 28872154PMID: 26844274PMID: 28753864); and introduction of state-of-the-art clinical trials (PMID: 26780387).

Developed and validated emerging diagnostic, prognostic, and therapeutic approaches through a long term (since 1993) bio-molecular specimen bank (230,000 units from 7000+ patients), e.g., ERG oncoprotein-based stratification of prostate cancer (PMID: 22331093) and Oncotype DX Prostate Cancer test (PMID: 25465337PMID: 26723180).